<DOC>
	<DOC>NCT01765114</DOC>
	<brief_summary>The aim of this study is therefore to investigate the efficacy of the PEG-formulation to reduce the frequency and duration of genital herpes recurrences, to assess its safety and tolerability and to investigate its effect on shedding.</brief_summary>
	<brief_title>A Study to Investigate the Efficacy, Safety and Tolerability of PEG in Patients With Genital Herpes</brief_title>
	<detailed_description />
	<mesh_term>Herpes Genitalis</mesh_term>
	<criteria>Informed Consent 18 65 years Positive for HSV1 and/or 2 (as determined by serology testing in course of study) Initial infection &gt; 1 year ago ≥ 6 recurrences in the last year (or in the year prior to a recent prophylactic therapy) ≥ 2 recurrences during the sixmonth baseline period Known or suspected allergy or intolerability to PEG Prophylactic antiviral drugs, virostatic agents, cytostatics, immunomodulatory drugs and steroids within less than 14 days prior to baseline period, or plan to take such drugs during the trial Pregnancy and/or breastfeeding History of malignant diseases (described in chapter 7.2) Known or suspected noncompliance to study protocol Participation in another investigational drug study in the last 30 days prior to baseline period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>